Amylyx Pharmaceuticals (AMLX) Change in Cash (2021 - 2026)

Amylyx Pharmaceuticals' Change in Cash history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 114.11% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $168.9 million, a 253.47% increase from a year earlier, with the FY2025 full-year figure at $148.8 million, up 261.59% from the prior year.
• Change in Cash climbed to $2.5 million in Q1 2026 per AMLX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Change in Cash topped out at $166.6 million in Q3 2025 and bottomed at -$112.5 million in Q3 2023.
• The 5-year median for Change in Cash is $1.5 million (2025), against an average of $10.6 million.
• Biggest YoY gain for Change in Cash was 6934.5% in 2025; the steepest drop was 5121.08% in 2025.
• Year by year, Change in Cash stood at -$45.2 million in 2022, then jumped by 177.29% to $34.9 million in 2023, then tumbled by 84.1% to $5.6 million in 2024, then slumped by 73.46% to $1.5 million in 2025, then surged by 68.54% to $2.5 million in 2026.
• Per Business Quant, the three latest AMLX Change in Cash figures stand at $2.5 million (Q1 2026), $1.5 million (Q4 2025), and $166.6 million (Q3 2025).